Medarex : Milestone Payment from FibroGen for the Initiation of a Phase 2 Study of FG-3019 in Patients with Diabetic Kidney Disease

Jul. 13, 2009-- Medarex, Inc. (NASDAQ:MEDX) announced it will receive a milestone payment of an undisclosed amount from its licensing partner, FibroGen,Inc., in connection with a recently initiated Phase 2 clinical trial of FG-3019 in patients with type 2 diabetes and advanced kidney disease as announced by FibroGen on June 15, 2009.



FG-3019 is a fully human monoclonal antibody generated using Medarex's UltiMAb(R) technology against connective tissue growth factor(CTGF). Under the agreement with FibroGen, Medarex could receive future milestone payments and sales-based royalty payments... Medarex's Press Release -

Kineta : Novel Drug Candidates from Airmid for Potential Treatment of Multiple Sclerosis, Type 1 Diabetes and other Autoimmune Diseases

July 7, 2009, – Kineta, Inc. of Seattle and Airmid Incorporated of Redwood City, CA jointly announce an agreement in which a Kineta subsidiary has acquired exclusive commercial rights to a portfolio of novel therapeutic compounds from Airmid. The array of compounds holds extraordinary potential for the treatment of multiple sclerosis, type 1 diabetes mellitus and numerous other autoimmune diseases...

...


Kineta, Inc. is a Seattle-based privately held biotechnology company specializing in clinical advancement of drugs that modulate and enhance the human immune system. Our world class scientists are pioneers, developing life-changing classes of drugs that harness the power of the immune system to fight disease. Kineta seeks to improve the lives of millions of people suffering from autoimmune and viral diseases... [PDF] Kineta's Press Release -

Andromeda Biotech Consummates Deal with Teva for the Commercialization of DiaPep277, its Late Stage Development Drug for Type 1 Diabetes

June 22, 2009 -- Teva completes $13.5 million investment in Andromeda and receives a worldwide exclusive license to commercialize DiaPep277 -- Andromeda Biotech Ltd. , announced that Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) has decided to exercise its option to complete a $13.5 million investment and license Andromeda’s DiaPep277 for the treatment of Type 1 diabetes. Pursuant to the agreements, Teva is receiving worldwide marketing rights for the DiaPep277 product...


... About Andromeda Biotech
Andromeda Biotech Ltd., a subsidiary of Clal Biotechnology Industries Ltd. (TASE: CBI), is focused on the development of an innovative treatment for autoimmune diabetes. Andromeda’s DiaPep277, currently in Phase III Clinical Studies, is a novel therapeutic approach in treating Type 1 diabetes. It is a unique peptide derived from the human protein, HSP60, which immunomodulates the immune system, prevents the destruction of pancreatic cells that secrete insulin and preserves their natural function... Andromeda Biotech's Press Release -